Moretto R, et al. - Researchers assessed the benefit derived from anti-epithelial growth factor receptor (EGFR) therapy among patients with RAS/BRAF wild-type metastatic colorectal cancer with and without mucinous histology. Overall, 22 mucinous or mucinous component tumors (11 right- and 11 left-sided tumors) and 83 non-mucinous tumors were included in the study population. According to this retrospective study, no meaningful benefit was observed with anti-EGFR therapy among those with either left- or right-sided tumors with mucinous histology. For the mucinous and not mucinous groups median progression-free survival was 2.8 vs 6.7 months, and the median overall survival was 6.5 and 16.7 months, respectively. These results were comparable to what was seen in subgroup analysis by primary tumor location.